linjc16/ctgov huggingface dataset:
Early Versus Late Stoma Closure After Traumatic Colorectal Injuries

Study Overview
=================
Brief Summary
-----------------
The aim is to study feasibility,advantages and disadvantages of early closure of stoma versus late closure of stoma

Detailed Description
-----------------
Most traumatic colon injuries can be repaired primarily, but a stoma may still be required for severe colonic or rectal injury. The current trend is to reverse the stoma early, rather than to wait the traditional 3 months before closure)1-3) Trauma patients, however, are usually young and otherwise healthy individuals, with an excellent potential for optimal healing once they have overcome the initial insult. It is these patients who could benefit from early closure of the stoma(4-6). Once the temporary stoma has been constructed, various reasons have been cited for the development of colon-related complications after closure. The timing of the operation, the age of the patient, the type of colostomy, and the use of primary or delayed skin closure have all been implicated(7-8). Of all these, the timing of the operation is the most controversial. The early closure of a temporary stoma has many attractions. It can reduce hospitalization time and cost, eliminates the need for stoma care by the patient, and abolishes the psychologic, social, and financial burdens of a stoma in an otherwise healthy person(9-11)

Official Title
-----------------
Early Versus Late Stoma Closure After Traumatic Colorectal Injuries

Conditions
-----------------
Stoma Colostomy

Intervention / Treatment
-----------------
* Procedure: stoma closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between (10-50) Exclusion Criteria: pathological causes deep, open perineal tear Severe co-morbid conditions (uncontrolled diabetes, Hypertension)

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: early closure of stoma<br>Detection complications of early closure of stoma in pateints with colorectal injures | Procedure: stoma closure<br>* early closure of stoma in trauma patients<br>|
| Active Comparator: late closure of stoma<br>Detection complications of late closure of stoma. | Procedure: stoma closure<br>* early closure of stoma in trauma patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early versus late stoma closure after traumatic colorectal injuries | Detection complications of early closuare of stoma | Baseline |
Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis

Study Overview
=================
Brief Summary
-----------------
Study of prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis

Detailed Description
-----------------
Detection of the prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis Study the relation between vertebral fractures and some clinical data like demographics data, disease duration and disease severity

Official Title
-----------------
Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis in Egyptian Patients and Its Relation to Some Clinical Data

Conditions
-----------------
Vertebral Fracture

Intervention / Treatment
-----------------
* Device: DEXA scan,X_ray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients fulfilling ACR/EULAR 2010 rheumatoid arthritis classification criteria. Patients diagnosed as ankylosing spondylitis according to ASAS criteria (2000). Age (18-50). Exclusion Criteria: Patient with other autoimmune Rheumatic disease other than RA and AS. Infections including hepatitis C or B, HIV, tuberculosis. RA and AS patients with known vertebral fractures. Malignancy, hypogonadism, thyroid problems, chronic kidney disease, Hypoparathyroidism, Type 1 DM. Pregnancy and breast-feeding.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RA group<br>DEXA scan X_rays lumber, dorsal spine | Device: DEXA scan,X_ray<br>* DEXA scan detect osteoporosis ,X_ray show subclinical vertebral fractures<br>|
| AS group<br>DEXA scan X_rays lumber, dorsal spine | Device: DEXA scan,X_ray<br>* DEXA scan detect osteoporosis ,X_ray show subclinical vertebral fractures<br>|
| Control group<br>DEXA scan X_rays lumber, dorsal spine | Device: DEXA scan,X_ray<br>* DEXA scan detect osteoporosis ,X_ray show subclinical vertebral fractures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of prevalence of subclinical vertebral fractures in RA ,AS and control group | Detection of prevalence of subclinical vertebral fractures in RA, AS and control group | Baseline |
SMCV Assessment on Brain Swelling in Patients With SAH

Study Overview
=================
Brief Summary
-----------------
Cerebral swelling is a major complication following aneurysmal subarachnoid hemorrhage.This study is a retrospective cohort aimed to predict the extent of brain swelling. Cerebral venous assessment can identify the risk of brain swelling and improve surgical outcomes.

Detailed Description
-----------------
Cerebral swelling is a major complication following aneurysmal subarachnoid hemorrhage (SAH).This study is a retrospective cohort aimed to predict the extent of brain swelling (BS). Cerebral venous assessment can identify the risk of cerebral swelling and improve surgical outcomes. This study is a retrospective cohort analysis. Cerebral venous angiography (CVA) will be adopted and the superficial middle cerebral vein (SMCVs) will be evaluated.

Official Title
-----------------
Cerebral Venous Assessment on Brain Swelling in Patients With Aneurysm Subarachnoid Hemorrhage: Retrospective Cohort Study

Conditions
-----------------
Aneurysm, Subarachnoid Hemorrhage, Brain Swelling

Intervention / Treatment
-----------------
* Procedure: Aneurysm embolization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with anterior communicating aneurysm Exclusion Criteria: Hunt-Hess grade I- patients with posterior communicating aneurysm, poor general condition or combined with pregnancy , malignant tumors were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Undeveloped venous group<br>patients with undeveloped cerebral venous | Procedure: Aneurysm embolization<br>* All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.<br>|
| Well Developed venous group<br>patients with well-developed cerebral venous | Procedure: Aneurysm embolization<br>* All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brain swelling | grading of brain swelling | 2 weeks |
Study of CM310 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.

Official Title
-----------------
Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Biological: CM310
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers. aged ≥ 18 and ≤ 65 years old. With all clinical laboratory examination normal. Voluntary signing of the informed consent form. Exclusion Criteria: With a history of asthma and allergic reactions. With a history of conjunctivitis and keratitis, as well as previous medical conditions. With positive results from alcohol breath or urine drug abuse testing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 75 mg<br>CM310 Recombinant Humanized Monoclonal Antibody Injection | Biological: CM310<br>* CM310 injection<br>|
| Experimental: Group 150 mg<br>CM310 Recombinant Humanized Monoclonal Antibody Injection | Biological: CM310<br>* CM310 injection<br>|
| Experimental: Group 300 mg<br>CM310 Recombinant Humanized Monoclonal Antibody Injection | Biological: CM310<br>* CM310 injection<br>|
| Experimental: Group 600 mg<br>CM310 Recombinant Humanized Monoclonal Antibody Injection | Biological: CM310<br>* CM310 injection<br>|
| Placebo Comparator: Placebo<br>Placebo, Subcutaneous | Drug: Placebo<br>* subcutaneous injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event | Incidence of adverse events. | up to Week 9 |
Evaluation of Rapid T2-weighted and DWI MR Sequences Reconstructed by Deep Learning for Prostate Imaging

Study Overview
=================
Brief Summary
-----------------
MR prostate exam is essential for the diagnosis, workup and follow-up of prostate cancer. It allows to detect subclinical prostate cancer following an increase in the level of PSA. The investigators can score the lesion according to the PIRADS classification and obtain an estimate of lesion malignancy. To perform this classification, T2 and DWI sequences are essential. Detection and characterization of malignant lesion is important to address appropriate patient care pathway. The purpose of this project is to evaluate novel deep learning (DL) T2-weighted TSE (T2DL) and Diffusion (DWIDL) sequences for prostate MR exam and investigate its impact on diagnostic, examination time, image quality, and PI-RADS classification compared to standard T2-weighted TSE (T2S) and standard Diffusion (DWIS) sequences.

Official Title
-----------------
Advanced DL-based T2w and DWI MR Sequences for Prostate Imaging

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: MR prostate exam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 ans Healthy subject without history of hepatic disease Patient addressed for an prostate MRI Ability to give consent Exclusion Criteria: claustrophobia, major obesity (>140 kg), Patient under guardianship or curators Age < 18 years, Women, History of prostatectomy or irradiation of the prostate any contraindication to MRI exam

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MR prostate exam|Subjects will lie in supine position. The systematic use of a headset will reduce the acoustic noise inherent to the machine. We are going to carry out the standard MR prostate protocol which patients usually benefit from in clinical routine. This protocol consists of morphological sequences (T2 weighting with spin echo readout), Diffusion MR and dynamic contrast-enhanced sequences. We will then perform an additional faster enhanced T2-weighting SE and DWI sequences combined with Deep Learning reconstruction|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in number of suspicious nodule prostate detection before and after rapid T2-weighted |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
T2 FSE, T2 DLR, diffusion DWI, diffusion DLR, Deep Learning Prostate cancer, PIRADS
Responsiveness of the Object Permanence Scale

Study Overview
=================
Brief Summary
-----------------
The aim of the study is the examining responsiveness of the Object Permanence Scale. The sample of the study will be 7-16 months old babies with motor developmental delay. Inclusion criteria: 7-16 months of age, sitting for at least 3 seconds but not being able to switch independently between sitting and other positions, and showing at least one developmental delay in the motor development subscale of the Bayley III Developmental Assessment. Evaluations will be done at baseline and 3 months. Exclusion criteria: Medical complications (eg, severe visual impairment) limiting participation in assessments; autism, down syndrome, or spinal cord injury; diagnosed uncontrolled seizure disorder; or a neurodegenerative disorder.

Official Title
-----------------
Responsiveness of the Object Permanence Scale

Conditions
-----------------
Developmental Delay

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 7-16 months, Sitting for at least 3 seconds but unable to independently switch between sitting and other positions To show at least one retardation in motor subscale of Bayley III. Exclusion Criteria: Medical complications (eg, severe visual impairment) limiting participation in assessments; autism, down syndrome, or spinal cord injury; diagnosed uncontrolled seizure disorder; or a neurodegenerative disorder

Ages Eligible for Study
-----------------
Minimum Age: 7 Months
Maximum Age: 16 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Object Permanence Scale | The minimum score of the Object Permanence Scale is 0, and the maximum score is 10. Higher scores indicate better outcome. | Baseline | 
| Object Permanence Scale | The minimum score of the Object Permanence Scale is 0, and the maximum score is 10. Higher scores indicate better outcome. | 3rd month | 
| The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) motor and cognitive subscales | Cognitive subscale consists of 91 items and Motor subscale consists of 138 items. Items are scored as 1 (done) and 0 (not able to). Higher scores indicate better outcome. | Baseline | 
| The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) motor and cognitive subscales | Cognitive subscale consists of 91 items and Motor subscale consists of 138 items. Items are scored as 1 (done) and 0 (not able to). Higher scores indicate better outcome. | 3rd month |
FoodImage 3 Free-Living

Study Overview
=================
Brief Summary
-----------------
Participants will be asked to use the app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from cabinet and refrigerator/freezer clean-outs. During collection of much of the food waste data, participants will record in the app if food waste will be disposed of via composting, disposal, fed to pets, or garbage/landfill. They will also indicate if the food was spoiled, past the expiration date, etc. This will occur for 4-8 days. Participants should perform the prep and eat occasions 4-8 days. The shopping and toss occasions should be completed for at least 7 days.

Official Title
-----------------
Multiscale RECIPES (Resilient, Equitable, and Circular Innovations With Partnership and Education Synergies) for Sustainable Food Systems (FoodImage 3; FI3) Free-Living

Conditions
-----------------
Waste Management, Food Supply, Climate, Nutrition Sciences

Intervention / Treatment
-----------------
* Other: Ad libitum data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female, age 18-65 years Willing to be recontacted Conducts some of the food shopping, food purchasing, and/or food preparation for their household. Internet and/or Wi-Fi availability to complete surveys and send images. Ownership of an iPhone 9S or later, operable Apple ID, password, and email address that they are willing and able to use to collect data during the study. Subject acknowledges data usage and associated charges are a result of study. Willing to complete all study procedures and adhere to study visit timelines - Exclusion Criteria: Refusal or unable to use an iPhone for study related purposes. Not willing to adhere to study procedures and study visit timelines. PBRC employee Any condition or circumstance that in the judgement of the PI could interfere with study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Free-Living<br> | Other: Ad libitum data collection<br>* Food purchase, prep, eat and toss data<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total weight of household food waste | weight (g) | daily during baseline collection |
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)

Study Overview
=================
Brief Summary
-----------------
The natural history study of patients with Sanfilippo disease(s) (MPS3)

Detailed Description
-----------------
This is a natural history study of patients with Sanfilippo Disease (MPS3). Patients will be followed over the course of 6 months in which they have blood and urine collected, hearing assessment, complete questionnaires and are evaluated by the Principal Investigator.

Official Title
-----------------
The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)

Conditions
-----------------
MPS3, Sanfilippo Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IRB - approved informed consent/assent signed by subject and/or parent(s) or legal guardian(s). Genetically confirmed diagnosis of MPS III disease Genomic DNA analysis demonstrating a homozygous or compound heterozygous pathogenic variants in SGSH (type A), NAGLU (type B), HGSNAT (type C), or N- acetylglucosamine-6-sulfatase GNS (type D). Male or female; five years of age and older Negative urine pregnancy test at screening for female subjects with child-bearing potential Exclusion Criteria: Unwilling or unable to follow protocol requirements as per principal investigator Any serious or chronic medical illness, including significant cardiac or severe debilitating pulmonary disease as determined by the investigator. Any medical condition that, in the opinion of the PI, would place a subject at undue risk Inability to cooperate for clinical and safety data collection Use of genistein or Miglustat within one week of the study Evidence of hepatitis B or hepatitis C infection upon serological testing at screening Currently participating in another interventional drug trial or has completed an interventional trial less than one month prior to the screening visit

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize the disease natural history in patients with MPS3. | To characterize the disease natural history in patients with MPS3. | 6 months |
Does Povidone-Iodine on Nail Affect Pulse Oximeter Reading?

Study Overview
=================
Brief Summary
-----------------
Povidone iodine is still a commonly used antiseptic in hospitals. Although pulse oximetry measurement is used as an important indicator in hospitals, no study has been found examining the effect of povidone iodine on the nail bed on the pulse oximetry result.

Detailed Description
-----------------
Povidone iodine is still a commonly used antiseptic in hospitals. Although pulse oximetry measurement is used as an important indicator in hospitals, no study has been found examining the effect of povidone iodine on the nail bed on the pulse oximetry result. The aim of this study is to determine the effect of 10% povidone iodine on the nail bed on the oxygen saturation reading in pulse oximetry.

Official Title
-----------------
Does Povidone-Iodine on Nail Affect Pulse Oximeter Reading?

Conditions
-----------------
HEALTHY INDIVIDUALS

Intervention / Treatment
-----------------
* Diagnostic Test: povidone iodine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteer person Healthy person Exclusion Criteria: Patients in hospital People with finger loss
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Measurement<br> | Diagnostic Test: povidone iodine<br>* Reference measurements were made simultaneously with two separate calibrated pulse oximeter devices from the index, middle and ring fingers of both hands of the participants. One layer of 10% povidone iodine was applied to the index finger, two layers to the middle finger, and three layers to the ring finger of one hand of the participant's choice. Two pulse oximetry measurements were made with the fingers of the other hand, immediately after the application of povidone-iodine and three minutes later, and it was noted on the data collection form.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of 10% povidone iodine in the nail bed on the SpO2 reading of the pulse oximeter |  | during the procedure |